Plus deals involving Lilly/Oblique, Rafael Holdings/Cyclo, ADCendo/Multitude, Ocuvex/Visiox and more.

Sepranolone may have progressed positively through a Phase IIa trial but its potential to reduce tics has failed to tempt any of the 20 or so potential partners that the Swedish biotech spoke to about a licensing deal.

C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.

Difficulties at two of its manufacturing facilities in Goa have led to a disappointing Q1 for Indoco, as the firm saw milestone payments delayed after receiving official action indicated status from the FDA.